Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Watson Pharmaceuticals was founded in 1984 in Corona, California. The company has facilities across the USA, and in Puerto Rico, the UK, Sweden and China. It vies with Barr and Mylan as the USA's largest generic manufacturer.

Watson's sales for 2006 showed an increase of 20.2% over 2005. Generic revenues amounted to around 75% of the total.

The company has always had a small branded business, introducing its first branded product in 1996. In February 2003, the FDA approved Oxytrol, the company's oxybutin product. This is the first product Watson has fully developed from conception to manufacturing and distribution.

In 2004, Watson Pharmaceuticals announced it is refocusing its product development and sales and marketing resources to concentrate on the urology, nephrology and generics business areas. Production at the Puerto Rico plant is being discontinued, and the US Steris injectables facility has been sold to Abraxis.

In March 2006, Watson announced it had entered into an agreement to acquire the outstanding stock of Andrx, in a deal worth some US$1.9 billion. The deal was completed in November 2006.